Bluejay Diagnostics Stock Short Ratio
| BJDX Stock | USD 3.48 0.14 3.87% |
Bluejay Diagnostics fundamentals help investors to digest information that contributes to Bluejay Diagnostics' financial success or failures. It also enables traders to predict the movement of Bluejay Stock. The fundamental analysis module provides a way to measure Bluejay Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bluejay Diagnostics stock.
Bluejay | Short Ratio |
Bluejay Diagnostics Company Short Ratio Analysis
Bluejay Diagnostics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Bluejay Diagnostics Short Ratio | 0.09 X |
Most of Bluejay Diagnostics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bluejay Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bluejay Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Bluejay Diagnostics is extremely important. It helps to project a fair market value of Bluejay Stock properly, considering its historical fundamentals such as Short Ratio. Since Bluejay Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bluejay Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bluejay Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Bluejay Diagnostics has a Short Ratio of 0.09 times. This is 97.69% lower than that of the Health Care Equipment & Supplies sector and 97.61% lower than that of the Health Care industry. The short ratio for all United States stocks is 97.75% higher than that of the company.
Bluejay Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bluejay Diagnostics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bluejay Diagnostics could also be used in its relative valuation, which is a method of valuing Bluejay Diagnostics by comparing valuation metrics of similar companies.Bluejay Diagnostics is currently under evaluation in short ratio category among its peers.
Bluejay Diagnostics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bluejay Diagnostics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bluejay Diagnostics' managers, analysts, and investors.Environmental | Governance | Social |
Bluejay Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Bluejay Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bluejay Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bluejay Diagnostics' value.| Shares | Sabby Management Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Anson Funds Management Lp | 2024-09-30 | 319.3 K | Renaissance Technologies Corp | 2024-09-30 | 137 K | Cvi Holdings Llc | 2024-06-30 | 66.2 K | Citadel Advisors Llc | 2024-09-30 | 52.2 K | Geode Capital Management, Llc | 2024-09-30 | 20.2 K | Virtu Financial Llc | 2024-06-30 | 17 K | Warberg Asset Management Llc | 2024-06-30 | 12.5 K |
Bluejay Fundamentals
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | (3.59 M) | ||||
| Shares Outstanding | 552.85 K | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 0.95 % | ||||
| Number Of Shares Shorted | 568.26 K | ||||
| Price To Book | 0.27 X | ||||
| Price To Sales | 54.99 X | ||||
| Gross Profit | 48.91 K | ||||
| EBITDA | (9.17 M) | ||||
| Net Income | (9.95 M) | ||||
| Cash And Equivalents | 15.34 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 352.98 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 17.41 X | ||||
| Book Value Per Share | 18.69 X | ||||
| Cash Flow From Operations | (8.31 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (804.00) X | ||||
| Target Price | 256.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 1.92 M | ||||
| Total Asset | 4.87 M | ||||
| Retained Earnings | (26.95 M) | ||||
| Working Capital | 1.45 M | ||||
| Net Asset | 4.87 M |
About Bluejay Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bluejay Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluejay Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluejay Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.